It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Histamine receptor 2 (H2R) blockade is commonly used in patients with gastric, duodenal ulcers or gastroesophageal reflux disease. Beyond the gastrointestinal tract, H2R is expressed by multiple immune cells, yet little is known about the immunomodulatory effects of such treatment. Clinical reports have associated H2R blockade with leukopenia, neutropenia, and myelosuppression, and has been shown to provide clinical benefit in certain cancer settings. To systematically assess effects of H2R blockade on key immune parameters, a single-center, single-arm clinical study was conducted in 29 healthy subjects. Subjects received daily high dose ranitidine for 6 weeks. Peripheral blood immunophenotyping and mediator analysis were performed at baseline, 3 and 6 weeks into treatment, and 12 weeks after treatment cessation. Ranitidine was well-tolerated, and no drug related adverse events were observed. Ranitidine had no effect on number of neutrophils, basophils or eosinophils. However, ranitidine decreased numbers of B cells and IL-2Rα (CD25) expressing T cells that remained lower even after treatment cessation. Reduced serum levels of IL-2 were also observed and remained low after treatment. These observations highlight a previously unrecognised immunomodulatory sustained impact of H2R blockade. Therefore, the immune impacts of H2R blockade may require greater consideration in the context of vaccination and immunotherapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Dalhousie University, Dalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200)
2 Dalhousie University, Dalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200); Dalhousie University, Senescence, Aging, Infection and Immunity Laboratory, Department of Medicine, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200); Nova Scotia Health Authority, Division of Infectious Diseases, Halifax, Canada (GRID:grid.458365.9) (ISNI:0000 0004 4689 2163)
3 Dalhousie University, Dalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200); Nova Scotia Health Authority, Division of Infectious Diseases, Halifax, Canada (GRID:grid.458365.9) (ISNI:0000 0004 4689 2163)